Literature DB >> 14990686

Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Shawn M Sumida1, Diana M Truitt, Michael G Kishko, Janelle C Arthur, Shawn S Jackson, Darci A Gorgone, Michelle A Lifton, Wouter Koudstaal, Maria G Pau, Stefan Kostense, Menzo J E Havenga, Jaap Goudsmit, Norman L Letvin, Dan H Barouch.   

Abstract

The high prevalence of preexisting immunity to adenovirus serotype 5 (Ad5) in human populations will likely limit the immunogenicity and clinical utility of recombinant Ad5 vector-based vaccines for human immunodeficiency virus type 1 and other pathogens. Ad5-specific neutralizing antibodies (NAbs) are thought to contribute substantially to anti-Ad5 immunity, but the potential importance of Ad5-specific T lymphocytes in this setting has not been fully characterized. Here we assess the relative contributions of Ad5-specific humoral and cellular immune responses in blunting the immunogenicity of a rAd5-Env vaccine in mice. Adoptive transfer of Ad5-specific NAbs resulted in a dramatic abrogation of Env-specific immune responses following immunization with rAd5-Env. Interestingly, adoptive transfer of Ad5-specific CD8(+) T lymphocytes also resulted in a significant and durable suppression of rAd5-Env immunogenicity. These data demonstrate that NAbs and CD8(+) T lymphocytes both contribute to immunity to Ad5. Novel adenovirus vectors that are currently being developed to circumvent the problem of preexisting anti-Ad5 immunity should therefore be designed to evade both humoral and cellular Ad5-specific immune responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990686      PMCID: PMC353774          DOI: 10.1128/jvi.78.6.2666-2673.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo.

Authors:  C Hofmann; P Löser; G Cichon; W Arnold; G W Both; M Strauss
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF.

Authors:  Dan H Barouch; Sampa Santra; Klara Tenner-Racz; Paul Racz; Marcelo J Kuroda; Joern E Schmitz; Shawn S Jackson; Michelle A Lifton; Dan C Freed; Helen C Perry; Mary-Ellen Davies; John W Shiver; Norman L Letvin
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

3.  Hexon gene switch strategy for the generation of chimeric recombinant adenovirus.

Authors:  Rima Youil; Timothy J Toner; Qin Su; Minchun Chen; Aimin Tang; Andrew J Bett; Danilo Casimiro
Journal:  Hum Gene Ther       Date:  2002-01-20       Impact factor: 5.695

4.  The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope.

Authors:  Melanie Olive; Laurence Eisenlohr; Neal Flomenberg; Susan Hsu; Phyllis Flomenberg
Journal:  Hum Gene Ther       Date:  2002-07-01       Impact factor: 5.695

5.  Overcoming immunity to a viral vaccine by DNA priming before vector boosting.

Authors:  Zhi-yong Yang; Linda S Wyatt; Wing-Pui Kong; Zoe Moodie; Bernard Moss; Gary J Nabel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  Replication-defective vector based on a chimpanzee adenovirus.

Authors:  S F Farina; G P Gao; Z Q Xiang; J J Rux; R M Burnett; M R Alvira; J Marsh; H C Ertl; J M Wilson
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes.

Authors:  V Molinier-Frenkel; H Gahery-Segard; M Mehtali; C Le Boulaire; S Ribault; P Boulanger; T Tursz; J G Guillet; F Farace
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

Review 9.  Prospects for vaccine protection against HIV-1 infection and AIDS.

Authors:  Norman L Letvin; Dan H Barouch; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

10.  Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product.

Authors:  Zhiquan Xiang; Guangping Gao; Arturo Reyes-Sandoval; Christopher J Cohen; Yan Li; Jeffrey M Bergelson; James M Wilson; Hildegund C J Ertl
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

View more
  74 in total

1.  Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.

Authors:  Lennart Holterman; Ronald Vogels; Remko van der Vlugt; Martijn Sieuwerts; Jos Grimbergen; Jorn Kaspers; Eric Geelen; Esmeralda van der Helm; Angelique Lemckert; Gert Gillissen; Sandra Verhaagh; Jerome Custers; David Zuijdgeest; Ben Berkhout; Margreet Bakker; Paul Quax; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

2.  The impact of pre-existing memory on differentiation of newly recruited naive CD8 T cells.

Authors:  Matthew D Martin; Thomas C Wirth; Peter Lauer; John T Harty; Vladimir P Badovinac
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

3.  Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.

Authors:  Sunil Kannanganat; Pragati Nigam; Vijayakumar Velu; Patricia L Earl; Lilin Lai; Lakshmi Chennareddi; Benton Lawson; Robert L Wilson; David C Montefiori; Pamela A Kozlowski; Bernard Moss; Harriet L Robinson; Rama Rao Amara
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

Review 4.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

5.  Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Authors:  Angelique A C Lemckert; Shawn M Sumida; Lennart Holterman; Ronald Vogels; Diana M Truitt; Diana M Lynch; Anjali Nanda; Bonnie A Ewald; Darci A Gorgone; Michelle A Lifton; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 6.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

7.  Plasmid DNA vaccine-elicited cellular immune responses limit in vivo vaccine antigen expression through Fas-mediated apoptosis.

Authors:  John R Greenland; Ralf Geiben; Sharmistha Ghosh; William A Pastor; Norman L Letvin
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422

8.  Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Authors:  Ariane Rodríguez; Jaap Goudsmit; Arjen Companjen; Ratna Mintardjo; Gert Gillissen; Dennis Tax; Jeroen Sijtsma; Gerrit Jan Weverling; Lennart Holterman; David E Lanar; Menzo J E Havenga; Katarina Radosevic
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

9.  Open-label phase I clinical trial of Ad5-EBOV in Africans in China.

Authors:  Lihua Wu; Zhe Zhang; Hainv Gao; Yuhua Li; Lihua Hou; Hangping Yao; Shipo Wu; Jian Liu; Ling Wang; You Zhai; Huilin Ou; Meihua Lin; Xiaoxin Wu; Jingjing Liu; Guanjing Lang; Qian Xin; Guolan Wu; Li Luo; Pei Liu; Jianzhong Shentu; Nanping Wu; Jifang Sheng; Yunqing Qiu; Wei Chen; Lanjuan Li
Journal:  Hum Vaccin Immunother       Date:  2017-07-14       Impact factor: 3.452

10.  Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.

Authors:  Eun Kim; Kaori Okada; Judy A Beeler; Roberta L Crim; Pedro A Piedra; Brian E Gilbert; Andrea Gambotto
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.